TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20569705
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers (53.9%)
Study: 20453720
Drug: Partner-delivered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partner-delivered therapy (PDPT)
Study: 16274808
Drug: Tinnitus retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus retraining therapy (TRT)
Study: 9875635
Drug: E2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 antibodies presence
Study: 7979464
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg three times a day for two weeks)
Study: 22789766
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 50/25 μg, 100/25 μg, and 200/25 μg, dosed once daily in the morning for 28 days
Study: 18534970
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (L3-4)
Study: 15831640
Drug: glipizide 5
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glipizide 5 mg/day
Study: 15831640
Drug: metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 500 mg/day
Study: 12182254
Drug: Piperacillin 12
Normalized name: PIPERACILLIN 12/TAZOBACTAM 1.5GM/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 12 g/tazobactam 1.5 g continuous infusion over 24 hours
Study: 12182254
Drug: Piperacillin 6
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin 6 g/tazobactam 0.75 g continuous infusion over 24 hours
Study: 12182254
Drug: Piperacillin 3
Normalized name: piperacillin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 3 g/tazobactam 0.375 g q6h for 24 hours
Study: 12182254
Drug: Piperacillin 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 6.75 g continuous infusion over 24 hours
Study: 10564834
Drug: PFD formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFD formulation
Study: 10564834
Drug: Saline formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline formulation
Study: 6777131
Drug: Metoclopramide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (administered orally in a double-blind fashion)
Study: 31253407
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (12 mg/L)
Study: 30239384
Drug: Lorazepam in
Normalized name: Lorazepam Intensol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam in combination with haloperidol
Study: 30239384
Drug: Benzodiazepines (scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines (scheduled doses or continuous infusion)
Study: 20048189
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and fluorouracil
Study: 18067659
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus antidepressants (UCandAD)
Study: 16279567
Drug: 0.1% olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% olopatadine hydrochloride ophthalmic solution, administered twice daily for 2 weeks in addition to nasal or systemic antiallergy medication.
Study: 16279567
Drug: No ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ocular therapy (control group), using only previously prescribed antiallergy medication for 2 weeks.
Study: 8061848
Drug: Spirapril 3
Normalized name: spirapril 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 3 mg once daily
Study: 3141101
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of a fermented milk test product supplying at least 2 X 10(9) live Lactobacillus acidophilus bacteria daily and 6.5% lactulose as substrate for the bacteria.
Study: 28279492
Drug: COX-1 inhibitor
Normalized name: COX-1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-1 inhibitor reactions
Study: 25289793
Drug: Nitrate gels
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate gels (NIT) + UV‐A
Study: 22520278
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis brief intervention (C-O)
Study: 22520278
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health brief intervention (H-O)
Study: 15517844
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and clonazepam
Study: 15517844
Drug: Sertraline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline and placebo
Study: 8441108
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered theophylline (aminophylline)
Study: 2874906
Drug: GRF 1-29
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRF 1-29 (1 microgram/kg i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Study: 2874906
Drug: TRH (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (200 micrograms/kg, i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Study: 29427527
Drug: Oral antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidants (vitamins C and E and α‐lipoic acid)
Study: 27861342
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy (diet and exercise counseling)
Study: 22615190
Drug: cilostazol plus
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cilostazol plus l-carnitine 1 g twice-daily
Study: 17702897
Drug: Eculizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab treatment in antithrombotic-treated patients (n = 103)
Study: 10496251
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 1.1 mg/d)
Study: 10496251
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean dose 1.2 mg/d)
Study: 9185259
Drug: Intramuscular anti-snake
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular anti-snake venom administration as a first aid measure
Study: 1684197
Drug: Parenterally-administered cephalosporin
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenterally-administered cephalosporin
Study: 24272966
Drug: D-ribose (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose (all doses)
Study: 18078723
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 25 mg
Study: 18078723
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 50 mg
Study: 18078723
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine 0 mg (control)
Study: 11239552
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg depot) every 28 days for 8 weeks
Study: 11239552
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg depot)
Study: 9727569
Drug: Immediate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate therapy (group A: ritonavir, zidovudine and lamivudine)
Study: 9727569
Drug: Delayed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed therapy (group B: ritonavir supplemented by zidovudine and lamivudine on day 21)
Study: 7958383
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G (4.8 mega units, intramuscularly), oral probenecid (1 g), and clavulanate-potentiated amoxycillin (375 mg tablet, orally)
Study: 16180594
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion (CPM) treatment
Study: 27002662
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (CPT) including active stretching, ROM and pendulum exercises
Study: 25487477
Drug: Single shot
Normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single shot bilateral intercostal block with levobupivacaine (L group)
Study: 19816834
Drug: Narrative exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative exposure therapy (NET)
Study: 12236631
Drug: Tianeptine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (37.5 mg)
Study: 10438552
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) plus standard medical treatment
Study: 20586748
Drug: Intracapsular local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracapsular local anaesthesia with 20 ml ropivacaine 0.5%
Study: 20586748
Drug: Intra-articular local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular local anaesthesia with 20 ml ropivacaine 0.5%
Study: 16321179
Drug: All types
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All types of reperfusion therapy
Study: 11904788
Drug: Ondansetron 24
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 24 mg once daily
Study: 2047061
Drug: Intravaginal prostaglandin
Normalized name: Intravaginal contraceptives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal prostaglandin E2 (PGE2) gel (2.0 mg, twice-weekly)
Study: 6996112
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron or intermittent iron supplement
Study: 30690141
Drug: Paclitaxel drug-coated
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel drug-coated balloon (DCB)
Study: 27214300
Drug: Lanreotide depot/autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide depot/autogel 120 mg
Study: 27762088
Drug: BBT plus
Normalized name: BBT-059
DrugBank: BBT-059 (DB18142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBT plus 50 mg ipragliflozin
Study: 27762088
Drug: BBT plus
Normalized name: BBT-059
DrugBank: BBT-059 (DB18142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBT plus 50 mg ipragliflozin and 20 mg teneligliptin
Study: 22844543
Drug: Liquefied carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquefied carbohydrate (CL, peach blended in 500 ml water + 250 ml water)
Study: 22844543
Drug: Solid carbohydrate
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid carbohydrate (CS, whole peaches + 750 ml water)
Study: 19232755
Drug: Amlodipine-based treatment
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-based treatment and atorvastatin 10 mg
Study: 15272513
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml ropivacaine 7.5 mg/ml
Study: 15272513
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml ropivacaine 7.5 mg/ml
Study: 15272513
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml ropivacaine 7.5 mg/ml (nerve block)
Study: 15272513
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml ropivacaine 7.5 mg/ml (nerve block)
Study: 9652426
Drug: Zidovudine, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 1000 mg daily for 24 weeks
Study: 1443451
Drug: Astemizole, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole, one 10-mg tablet each morning for 4 weeks
Study: 2935051
Drug: Cimetidine, 300
Normalized name: Cimetidine, 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 300 mg every 6 hr
Study: 2935051
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg every 12 hr
Study: 2935051
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no other treatment)
Study: 29228392
Drug: Ombitasvir/paritaprevir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with no RBV for the first 2 weeks followed by weight-based dosing thereafter (Arm A)
Study: 29228392
Drug: Ombitasvir/paritaprevir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombitasvir/paritaprevir/ritonavir plus dasabuvir with low-dose RBV (600 mg) once daily for all 12 weeks (Arm C)
Study: 16297747
Drug: 1‐ to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐ to 1.5‐microg/kg dose of fentanyl
Study: 11977539
Drug: CGS 20267
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20267 0.5 mg once daily
Study: 11977539
Drug: CGS 20267
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20267 1.0 mg once daily
Study: 2406330
Drug: Calcitonin (415
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (415 pmol i.v. bolus injection followed by a 90‐min infusion to reach an overall dose of 62.25 pmol/kg body mass)
Study: 6988522
Drug: Gentamicin (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (normal or subnormal doses)
Study: 23348146
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg bid
Study: 19057212
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injection into the prostate
Study: 17724497
Drug: Dalbavancin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin (1 g followed by 500 mg one week later)
Study: 15492164
Drug: Placebo (BSS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (BSS Sterile Irrigating Solution)
Study: 7813167
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day for six months)
Study: 7813167
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day for six months)
Study: 2684107
Drug: Cefotaxime sodium,
Normalized name: Cefotaxime Sodium, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime sodium, 3 x 2 g/d, intravenously (n = 11)
Study: 2684107
Drug: Penicillin G,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin G, 4 x 5 million U/d (n = 10)
Study: 2684107
Drug: Cefotaxime and
Normalized name: cefotaxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime and Penicillin G
Study: 1108695
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of cocaine dissolved in 2 ml of saline without adrenaline
Study: 1108695
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg of cocaine
Study: 1108695
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of cocaine
Study: 31359734
Drug: Fuyanshu Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuyanshu Capsules combined with levofloxacin hydrochloride and metronidazole for 56 days and 14 days respectively
Study: 31359734
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received Fuyanshu Capsules as its analogue
Study: 23381958
Drug: ACT-178882 100
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-178882 100 mg single dose
Study: 23381958
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg once a day for 13 days + ACT-178882 100 mg single dose on day 4
Study: 21690070
Drug: 4% gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% gelofusine solution at the rate of 20 ml/kg/h 30 min before the operation
Study: 21690070
Drug: Lactated Ringers
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringers solution at 4 ml/kg/h for maintenance of total blood volume
Study: 19757979
Drug: Biomedical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine)
Study: 19757979
Drug: Biomedical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine) with TCM cold pattern
Study: 19757979
Drug: Biomedical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomedical combination therapy (diclofenac, methotrexate, and sulfasalazine) with TCM hot pattern
Study: 9398103
Drug: Digitalis (deslanoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis (deslanoside 0.01 mg/kg)
Study: 7514506
Drug: Hydromorphone PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone PCA (0.1 mg/hr basal infusion, 0.2 mg Q 5 min bolus, max 1.2 mg/hr)
Study: 7514506
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic therapy (CAT) with morphine 2.5 mg iv Q 30 min prn until extubation, followed by meperidine 1 mg/kg im Q 4 hr or acetaminophen 325 mg with codeine 30 mg po (1 or 2 tablets) when oral intake possible
Study: 31949115
Drug: Gefapixant (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefapixant (doses ≥30 mg)
Study: 31949115
Drug: Gefapixant (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefapixant (doses ≥150 mg)
Study: 28379925
Drug: Medically graded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medically graded bee honey at 5 g/day
Study: 28379925
Drug: Medically graded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medically graded bee honey at 10 g/day
Study: 28379925
Drug: Medically graded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medically graded bee honey at 15 g/day
Study: 28379925
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g/day honey)
Study: 22229233
Drug: intradermal non-absorbable
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal non-absorbable suture
Study: 22229233
Drug: intradermal non-absorbable
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal non-absorbable double layer suture
Study: 12970916
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) and enteral nutrition (EN) therapies
Study: 12970916
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) via central venous infusion
Study: 8599322
Drug: 56.3 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56.3 mmol acetate/L
Study: 8599322
Drug: 18.7 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.7 mmol propionate/L
Study: 8599322
Drug: 18.7 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.7 mmol acetate/L
Study: 8599322
Drug: 56.3 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56.3 mmol propionate/L
Study: 1457388
Drug: 10 mg/ml
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/ml fluphenazine decanoate formulation
Study: 1457388
Drug: 25 mg/ml
Normalized name: hemin 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/ml standard fluphenazine decanoate formulation
Study: 1457388
Drug: Pre-injection serum
Normalized name: antirabies serum,equine Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-injection serum fluphenazine levels in a subgroup of 10 patients
Study: 6374050
Drug: Doxorubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-based chemotherapy regimens (cyclophosphamide and doxorubicin alone or in combination with methotrexate or cisplatin)
Study: 6374050
Drug: Doxorubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-based chemotherapy regimens
Study: 31192908
Drug: Sustained-release oxycodone
Normalized name: oxycodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oxycodone (tablets, 12 hourly)
Study: 31192908
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine (5 mg initially, hourly)
Study: 17889760
Drug: Henderson capsule
Normalized name: Primula hendersonii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henderson capsule tension ring (HCTR, Morcher)
Study: 11441370
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg) in the acute study
Study: 11441370
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg/d) in the chronic study
Study: 4570092
Drug: Antimicrobial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial treatment and anti-diarrheal agents
Study: 21868779
Drug: Exenatide (EXE)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EXE) and Insulin glargine (GLAR)
Study: 16613177
Drug: Reperfusion therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy, thrombolysis, or percutaneous coronary intervention
Study: 16613177
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with various pharmacological agents
Study: 10989852
Drug: Fibreoptic intubation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibreoptic intubation through the intubating laryngeal mask (Group L)